**FOR IMMEDIATE RELEASE**
WILMINGTON, Del. – May 30, 2026 – Incyte’s frontMIND trial revealed that the combination of tafasitamab (Monjuvi®/Minjuvi®) with other treatments significantly extended progression-free survival in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). The study demonstrated a 25% reduction in the risk of disease progression or death among patients receiving the tafasitamab combination.
The pivotal frontMIND trial evaluated the efficacy of adding tafasitamab to the standard treatment regimen for high-risk DLBCL. Researchers found that patients treated with the tafasitamab combination experienced a notable improvement in progression-free survival compared to those receiving the standard treatment alone. This outcome indicates that the addition of tafasitamab offers a substantial clinical benefit by delaying disease progression and improving overall outcomes for this patient population…